Company news
Astellas Pharma Inc. (TSE:4503) news
Every Astellas Pharma Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
September 1, 2026
Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines
August 31, 2026
Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
August 24, 2026
Financial Results (Q1 YTD/FY2026)
August 5, 2026
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
July 10, 2026
Ono Pharmaceutical : Pharma Submits a Supplemental Application in Japan to Expand the Use of OPDIVO for the Treatment of Unresectable Anaplastic Thyroid Cancer
June 11, 2026
Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company
May 26, 2026
Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
May 18, 2026
Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo
May 13, 2026
IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients
May 12, 2026
Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting
April 30, 2026
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
April 20, 2026
Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design
April 8, 2026
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
February 27, 2026
Melodia Therapeutics Announces U.S. Patent Grant Covering MLD-151
February 25, 2026
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
February 23, 2026
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development
February 18, 2026
VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
January 8, 2026
Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 17, 2025
Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines
December 11, 2025
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
December 10, 2025
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
December 5, 2025
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
November 21, 2025
Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
October 23, 2025
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
October 22, 2025
PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
October 21, 2025
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
October 19, 2025
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
October 18, 2025
Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
October 13, 2025
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
October 13, 2025
Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
October 8, 2025
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
October 1, 2025
Astellas Announces Top Management Personnel Change
September 29, 2025
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
August 12, 2025
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"
July 17, 2025
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
June 13, 2025
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
May 29, 2025
Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers
May 28, 2025
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
May 22, 2025
Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
May 21, 2025
Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting
May 19, 2025
Notice of Nominees for Directors
May 7, 2025
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
May 1, 2025
U.S. FDA Approves Expanded Label for Astellas IZERVAY for Geographic Atrophy
February 13, 2025
Astellas Pharma Inc. - Recording of Extraordinary Losses in Non-consolidated Financial Results
February 6, 2025
Astellas Pharma - China's National Medical Products Administration Approves VYLOY for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
January 6, 2025
Astellas VYLOY Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
October 21, 2024